Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02588612 · ClinicalTrials.gov registry record · Phase 1
Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02588612 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 10 participants.
The verdict
NCT02588612, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This trial will evaluate safety and efficacy of letetresgene autoleucel (GSK3377794) in participants with metastatic NSCLC.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG letetresgene autoleucel (GSK3377794)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-02-01 |
| Est. Completion | 2020-08-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02588612
The ClinicalTrials.gov registry entry for NCT02588612 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT02588612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02588612 about?
NCT02588612 is a clinical study titled "Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)". This trial will evaluate safety and efficacy of letetresgene autoleucel (GSK3377794) in participants with metastatic NSCLC.
What is the current status of trial NCT02588612?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2016-02-01. Estimated completion is 2020-08-10.
What interventions are being tested in trial NCT02588612?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), letetresgene autoleucel (GSK3377794) (DRUG).
Who is sponsoring clinical trial NCT02588612?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.